Literature DB >> 16860779

Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.

Yann S Mineur1, Marina R Picciotto, Gerard Sanacora.   

Abstract

BACKGROUND: Excessive glutamatergic neurotransmission is hypothesized to be associated with depressive-like behaviors and possibly major depressive disorder (MDD). Recent evidence that beta-lactam antibiotic agents stimulate uptake of glutamate suggests that this class of compounds might possess antidepressant-like activity.
METHODS: Three-month old, male, C57BL/6J mice were administered ceftriaxone (200 mg/kg IP) for 14-18 days, then tested in the tail-suspension, forced swim, and novelty-suppressed feeding tests to determine whether ceftriaxone had similar effects to classical antidepressant compounds in these models.
RESULTS: Ceftriaxone treatment had an antidepressant-like effect across models. Reduced immobility and decreased freezing were observed in the forced swim and tail suspension tests. The same trend was seen in novelty-suppressed feeding, but the effect was not statistically significant.
CONCLUSION: Ceftriaxone demonstrates antidepressant-like effects in several mouse models. This is consistent with the hypothesis that enhanced uptake of glutamate might have antidepressant-like effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860779     DOI: 10.1016/j.biopsych.2006.04.037

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  55 in total

1.  Human nasal olfactory epithelium as a dynamic marker for CNS therapy development.

Authors:  Rita Sattler; Yoko Ayukawa; Luke Coddington; Akira Sawa; David Block; Richard Chipkin; Jeffrey D Rothstein
Journal:  Exp Neurol       Date:  2011-09-16       Impact factor: 5.330

2.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

3.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 4.  Overview of glutamatergic neurotransmission in the nervous system.

Authors:  Mark J Niciu; Benjamin Kelmendi; Gerard Sanacora
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

5.  Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action.

Authors:  Jing Du; Rodrigo Machado-Vieira; Sungho Maeng; Keri Martinowich; Husseini K Manji; Carlos A Zarate
Journal:  Drug Discov Today Ther Strateg       Date:  2006

6.  Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress.

Authors:  Jian-Xin Chen; Li-Hua Yao; Bi-Bo Xu; Kun Qian; Hui-Ling Wang; Zhong-Chun Liu; Xiao-Ping Wang; Gao-Hua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 7.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

Review 8.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

10.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.